| Inclusion Criteria: | 1) No anti-cancer therapy for three weeks (six weeks if Rituximab, nitrosourea or Mitomycin C) prior to study initiation, and fully recovered from acute toxicities associated with prior surgery, radiation treatments, chemotherapy, or immunotherapy.
2) Previously treated patients with a histology of refractory/relapsed indolent lymphomas including: (a) Extranodal marginal lymphoma of MALT type; (b) Nodal Marginal zone B-cell lymphoma (+/- monocytoid cells); (c) Splenic marginal B-cell lymphoma (+/- villous lymphocytes).
3) Signed informed consent
4) Age >/= 18 years
5) Expected survival >/= 3 months
6) Pre-study Zubrod performance status of 0, 1, or 2
7) Acceptable hematologic status within two weeks prior to patient registration, including: (a) Absolute neutrophil count ([segmented neutrophils + bands] x total WBC) >/= 1,500/mm^3; (b) Platelet counts >/= 100,000/mm^3.
8) Female patients who are not pregnant or lactating
9) Men and women of reproductive potential who are following accepted birth control methods (as determined by the treating physician)
10) Patients previously on Phase II drugs if no long-term toxicity is expected, and the patient has been off the drug for eight or more weeks with no significant post treatment toxicities observed
11) Patients determined to have < 25% bone marrow involvement with lymphoma within six weeks of registration (define measurement of a bone marrow aspirate or biopsy) (This criteria must be strictly met for adequate patient safety.)
12) Patient should have at least one lesion measuring >/= 2 cm in a single dimension. |